NCT01781520

Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer

Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined With S-1 in Patients With Advanced Pancreatic Cancer: A Prospective Study.

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Capital Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK) for unresectable locally advanced pancreatic cancer.

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
BIOLOGICAL	DC-CIK Treatment	The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
DRUG	S1	The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25-\<1.5 m2, 50 mg; and \>1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
OTHER	Best supportive care	Best supportive care

Timeline

• Start date: 2013-06-01
• Primary completion: 2016-05-30
• Completion: 2017-06-13
• First posted: 2013-02-01
• Last updated: 2018-01-18

Locations

1 site across 1 country: China